Juvenile Rheumatoid Arthritis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Juvenile Rheumatoid Arthritis pipeline constitutes 8+ key companies continuously working towards developing 10+ Juvenile Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Juvenile Rheumatoid Arthritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Juvenile Rheumatoid Arthritis Market.

The Juvenile Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Juvenile Rheumatoid Arthritis Pipeline Report: https://www.delveinsight.com/sample-request/juvenile-rheumatoid-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Juvenile Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.
• Juvenile Rheumatoid Arthritis companies working in the treatment market are Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others, are developing therapies for the Juvenile Rheumatoid Arthritis treatment
• Emerging Juvenile Rheumatoid Arthritis therapies in the different phases of clinical trials are- Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept and others are expected to have a significant impact on the Juvenile Rheumatoid Arthritis market in the coming years.
• In April 2025, The European Medicines Agency (EMA) has approved Cullinan Therapeutics' clinical trial application for CLN-978, a prospective therapy for rheumatoid arthritis (RA). This Phase I open-label study will include patients with active, treatment-resistant RA, according to the 2010 ACR/EULAR classification criteria. The trial aims to assess the drug's pharmacokinetics, pharmacodynamics, safety, and impact on disease activity.
• In October 2024, SetPoint Medical has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA), allowing it to start a clinical trial to test its modulation platform in relapsing-remitting multiple sclerosis (RRMS) patients. The multicenter, randomized, double-blind, sham-controlled pilot study will take place in the US and is set to begin in 2025. The US-based company plans to enroll 60 patients with the autoimmune disorder for the trial.
• In July 2024, Navidea Biopharma has decided to discontinue its Juvenile Rheumatoid Arthritis (RA) program following unsatisfactory findings from an exploratory analysis of the NAV3-33 trial. The Phase III study (NCT05246280), which included 523 participants, aimed to validate the effectiveness of intravenous (IV) Lymphoseek (Tc 99m tilmanocept) imaging in predicting clinical outcomes in RA patients starting anti-tumor necrosis factor alpha (TNFα) therapy.
• In July 2024, Dutch biotech firm Citryll has completed subject dosing in the repeat-dose phase of its Phase I clinical trial for CIT-013, an anti-inflammatory drug candidate. This first-in-human study focuses on evaluating the safety and tolerability of the antibody. In the trial's part D segment, the safety and tolerability of CIT-013 are further assessed through repeat dosing in a group of nine Juvenile Rheumatoid Arthritis (RA) patients and three healthy volunteers.

Juvenile Rheumatoid Arthritis Overview
Juvenile idiopathic arthritis (JIA), also known as juvenile rheumatoid arthritis (JRA), is the most common form of arthritis in children under the age of 16. It is a chronic autoimmune disease characterized by inflammation in the joints, which leads to pain, stiffness, swelling, and sometimes loss of joint function.

Get a Free Sample PDF Report to know more about Juvenile Rheumatoid Arthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/juvenile-rheumatoid-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Juvenile Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:
• Sarilumab (Kevzara): Regeneron/Sanofi
• Baricitinib: Eli Lilly and Company
• Certolizumab pegol: UCB BIOSCIENCES GmbH
• Upadacitinib: AbbVie
• Tofacitinib: Pfizer
• Sarilumab SAR153191 (REGN88): Sanofi
• GenaKumab: Changchun GeneScience Pharma
• AIN457: Novartis
• Etanercept: Istituto Giannina Gaslini

Juvenile Rheumatoid Arthritis Route of Administration
Juvenile Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Juvenile Rheumatoid Arthritis Molecule Type
Juvenile Rheumatoid Arthritis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Juvenile Rheumatoid Arthritis Pipeline Therapeutics Assessment
• Juvenile Rheumatoid Arthritis Assessment by Product Type
• Juvenile Rheumatoid Arthritis By Stage and Product Type
• Juvenile Rheumatoid Arthritis Assessment by Route of Administration
• Juvenile Rheumatoid Arthritis By Stage and Route of Administration
• Juvenile Rheumatoid Arthritis Assessment by Molecule Type
• Juvenile Rheumatoid Arthritis by Stage and Molecule Type

DelveInsight's Juvenile Rheumatoid Arthritis Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Juvenile Rheumatoid Arthritis product details are provided in the report. Download the Juvenile Rheumatoid Arthritis pipeline report to learn more about the emerging Juvenile Rheumatoid Arthritis therapies at:
https://www.delveinsight.com/sample-request/juvenile-rheumatoid-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Juvenile Rheumatoid Arthritis Therapeutics Market include:
Key companies developing therapies for Juvenile Rheumatoid Arthritis are - Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., and others.

Juvenile Rheumatoid Arthritis Pipeline Analysis:
The Juvenile Rheumatoid Arthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Juvenile Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Juvenile Rheumatoid Arthritis Treatment.
• Juvenile Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Juvenile Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Juvenile Rheumatoid Arthritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Juvenile Rheumatoid Arthritis drugs and therapies-
https://www.delveinsight.com/sample-request/juvenile-rheumatoid-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Juvenile Rheumatoid Arthritis Pipeline Market Drivers
• Rising prevalence of arthritis and other joint disorders, rising combinational therapy of biologics for the treatment of Juvenile Rheumatoid Arthritis, rich emerging pipeline, acceptance of biosimilars for treatment of Juvenile Rheumatoid Arthritis are some of the important factors that are fueling the Juvenile Rheumatoid Arthritis Market.

Juvenile Rheumatoid Arthritis Pipeline Market Barriers
• However, high cost of biologics, low adherence to the drugs, lack of daily assessment of RA • Delay in RA diagnosis and other factors are creating obstacles in the Juvenile Rheumatoid Arthritis Market growth.

Scope of Juvenile Rheumatoid Arthritis Pipeline Drug Insight
• Coverage: Global
• Key Juvenile Rheumatoid Arthritis Companies: Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others
• Key Juvenile Rheumatoid Arthritis Therapies: Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others
• Juvenile Rheumatoid Arthritis Therapeutic Assessment: Juvenile Rheumatoid Arthritis current marketed and Juvenile Rheumatoid Arthritis emerging therapies
• Juvenile Rheumatoid Arthritis Market Dynamics: Juvenile Rheumatoid Arthritis market drivers and Juvenile Rheumatoid Arthritis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.